Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 211,140,982 papers from all fields of science
Search
Sign In
Create Free Account
Etanidazole
Known as:
1H-Imidazole-1-acetamide, N-(2-hydroxyethyl)-2-nitro-
, 2-Nitroimidazole-1-acetamide, N-(2-hydroxyethyl)-
, Etanidazole [Chemical/Ingredient]
A 2-nitroimidazole with radiosensitizing properties. Etanidazole depletes glutathione and inhibits glutathione transferase, thereby enhancing the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
15 relations
Narrower (3)
2-nitroimidazole EF5
SR-2508
fluoroetanidazole
Broader (3)
Antineoplastic Agents
Nitroimidazoles
Radiation-Sensitizing Agents
Glutathione S-Transferase
In Blood
agonists
analogs & derivatives
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.
J. Brown
,
M. Diehn
,
B. Loo
International Journal of Radiation Oncology…
2010
Corpus ID: 205360364
Highly Cited
2002
Highly Cited
2002
Double-walled microspheres for the sustained release of a highly water soluble drug: characterization and irradiation studies.
Teng Huar Lee
,
Jianjun Wang
,
Chi‐Hwa Wang
Journal of Controlled Release
2002
Corpus ID: 26978705
Highly Cited
1998
Highly Cited
1998
Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.
W. Lee
,
B. Berkey
,
+6 authors
H. Ortiz
International Journal of Radiation Oncology…
1998
Corpus ID: 32854488
Highly Cited
1995
Highly Cited
1995
Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity.
C. Koch
,
S. Evans
,
E. Lord
British Journal of Cancer
1995
Corpus ID: 16609339
The present studies were initiated to quantitate the oxygen dependence of bioreductive metabolism-induced binding of EF5, a…
Expand
1995
1995
Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity.
N. Oya
,
Y. Shibamoto
,
+6 authors
M. Abe
International Journal of Radiation Oncology…
1995
Corpus ID: 5850856
Highly Cited
1994
Highly Cited
1994
Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors.
J. Overgaard
Oncology Research
1994
Corpus ID: 41085503
Hypoxic modification by nitroimidazoles has been explored in a large number of clinical studies. Nine different drugs…
Expand
Review
1993
Review
1993
Local hyperthermia, radiation therapy, and chemotherapy in patients with local-regional recurrence of breast carcinoma.
B. Bornstein
,
P. S. Zouranjian
,
+4 authors
G. Svensson
International Journal of Radiation Oncology…
1993
Corpus ID: 11374781
Highly Cited
1993
Highly Cited
1993
Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.
E. Lord
,
L. Harwell
,
C. Koch
Cancer Research
1993
Corpus ID: 22289916
Hypoxic cells in tissue pose many medical problems, and there is a need for more accurate measurements of tissue hypoxia. However…
Expand
Highly Cited
1990
Highly Cited
1990
Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
B. Teicher
,
S. Holden
,
A. Al-Achi
,
T. Herman
Cancer Research
1990
Corpus ID: 17277787
In order to investigate the effect of environmentally determined conditions on the cytotoxicity of anticancer treatments, Hoechst…
Expand
Review
1989
Review
1989
Keynote address: hypoxic cell radiosensitizers: where next?
J. Brown
International Journal of Radiation Oncology…
1989
Corpus ID: 13335389
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE